Albert L. Sokol: Lawyer with Edwards Wildman Palmer LLP

Albert L. Sokol

View Albert L. Sokol 's Martindale-Hubbell Connected Profile
Partner
Boston,  MA  U.S.A.
Phone617-951-2237

Peer Rating
N/R
 N/R

Client Rating

Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials
 

Practice Areas

  • Business Law
  • Mergers & Acquisitions
  • Private Equity
  • Venture Capital
  • Securities Offerings and Public Company Counseling
  • Licensing
  • Collaborations
  • Joint Ventures & Strategic Alliances
  • Cross Border
  • Emerging Markets
  • Life Sciences
  • Technology
  • Energy & Cleantech
  • Telecommunications
 
University Yale University, B.A., 1970
 
Law SchoolBoston University School of Law, J.D., 1977
 
Admitted1977, Massachusetts
 
Memberships 

Memberships

Massachusetts Biotechnology Council
Massachusetts Software Council
European Venture Capital Association
Chambers of Commerce of France, Australia, Germany, Sweden, UK

 
BornSidney, New York, May 10, 1948
 
Biography

Al represents life sciences, IT/Technology and other businesses and investors in venture capital and private equity, corporate work, mergers/acquisitions, collaborations, spin-offs, strategic alliances, licenses, and management compensation issues. Much of his work involves cross-border situations. Al works hard to understand his clients' markets and business objectives.

Al has been recognized for several years by the Practical Law Company as Recommended in M&A and Corporate Transactions. He has also been listed as a Super Lawyer byLaw & Politics andBoston Magazinein the areas of Securities & Venture Finance.
•For a legged robotics company that spun off from a major university 20 years ago, general corporate representation, and finally, merger with large, high-profile technology company.

•For the venture capital funds of two pharmaceutical companies (one U.S., one foreign), equity investment in a biotechnology company (oncology), having been spun off from a major research university.

•For a Swedish printed circuit board company, two separate acquisitions of U.S. competitors, one in the Northeast and the other in the Mid-West.

•For a venture-funded biotechnology company having platform IP that is used to target cancer, restructured from a single C corporation to a limited liability company (LLC), to achieve benefits of a multiple-asset-centric structure, plus assistance with financings, employee benefits, commercial issues, and other tasks.

•For a Canadian telecom equipment company (multi-wavelength laser, with advanced photonics, characterized by innovative power, size and cost parameters for data centers), venture capital financing and corporate work.

•For a venture-funded biotechnology company with platform IP for optimizing metal-binding elements of compounds, restructuring from a single C corporation to a limited liability company (LLC), to achieve benefits of a multiple-asset-centric structure, plus assistance with financings, employee benefits, commercial issues, and other tasks.

•For venture capital fund of a pharmaceutical company, many equity investments in U.S. biotechnology companies.

•For publicly traded cleantech company (composites, hardware, software), for 13 years, corporate counselling of company and its board of directors, and IPO, multiple venture capital financings, multiple PIPEs, governmentally-guaranteed loans, litigation, licensing, employment issues, and intellectual property work.

•For a Japanese life sciences client's transaction with a U.S. company, strategic alliance covering loan, equity conversion, licensing, production and supply arrangements.

•For a venture-funded, German-based telecommunications client, during 10 years, spin off, multiple financings with UK, Belgian, Swiss, German, U.S. and Japanese investors, M&A, licensing, HR, and other work, and then an M&A exit for its sale to a U.S. telecommunications equipment company buyer.

•Sale of a Swiss life sciences services company to U.S. buyer.

•For the venture capital fund of a foreign pharmaceutical company, many equity investments in biotechnology and life sciences companies, and also a limited partner equity investment in a venture capital fund.

•Acquisition in the U.S. by a public biopharmaceutical company in Germany of an oncology diagnostics operating division of a medical devices company.

•Acquisition by a Danish engineering company of a U.S. engineering company.

•For Pacific Rim, public pharmaceutical company, and over a period of nearly 25 years, acquisition of Swedish biotech company; stock incentive arrangements in the U.S. for U.S. employees; acquisition (and, then divestment, 10 years later) of global sera and cell culture reagents business in U.S. (four states), Europe (UK and Germany) and Australia; and various licensing/IP transactions.

•Assisted many non-U.S. companies in setting up U.S. operations, in various industries, e.g., bone medical devices, pulmonary resuscitation devices, in vitro fertilization, enterprise software for financial management, asset management for financial services companies, complex resource optimization, water purity, certification of business processes, travel security, and other industries.

•For a European resource optimization software company, over a period of 6 years, acquisition of an Australian company, venture capital financing, other M&A activity, several major IT transactions in the transportation industry, and merger with large, high-profile technology company.

•Assisted various foreign banks in U.S. aspects of credit arrangements with borrowers with U.S. operations.

•For the first commercial in vitro fertilization company in the U.S., financings, corporate governance, corporate and other work

•Collaboration and licensing agreements for European, Australian and U.S. life sciences clients with U.S. and European companies, relating to anti-infective, vaccine, drug delivery and other life science technologies.

•Investment due diligence on patents, contracts, executive compensation and deal structure for European venture capital and other investors in U.S. and European companies.

•For a French biotech company, acquisition arrangements relating to a U.S. vaccine company.

•Eight acquisitions in four countries during a twelve-month period for a venture-funded software client with operations in the U.S., Europe and Australia.

•Acquisition of an internet security company from French sellers and (separately) disposition of a different internet security company to a French public buyer, and various financings with investors from France, Australia, the U.S. and Scandinavia.

Regions

Central and Eastern Europe (CEEMENA)

Scandinavian & Nordic Region

South Asia

Before Edwards Wildman

After attending Yale University, Al moved to Lusaka, Zambia, for three years of micro-credit activities, primarily as the number two executive of the National Credit Union Association of Zambia. He also has taken post-graduate courses at the University of Ghana, Africa, and the University of Poitiers, France.

Besides Edwards Wildman

Al led a group of corporate executives in a visit to 15-20 large factories in the former Soviet Union in late 1991, traveling down the Volga River via riverboat. Al is an enthusiastic sea kayaker (with four sea kayaks), hiker, and cross-country skier. He is married to a Dane and has two sons.

 
ISLN903563886
 
Profile Visibility
#650 in weekly profile views out of 19,408 lawyers in Boston, Massachusetts
#46,918 in weekly profile views out of 1,537,162 total lawyers Overall

Office Information

Albert L. Sokol

111 Huntington Avenue
BostonMA 02199-7613




Loading...
 

Professional Networking for Legal Professionals Only

Quickly and easily expand your professional
network - join the premier global network for legal professionals only. It's powered by the
Martindale-Hubbell database - over 1,000,000 lawyers strong.
Join Now